The two workshops on Haploidentical Stem Cell Transplantation were held in Italy and in the USA to communicate the achievements to date in this field. In the past decade, the histoincompatibility barrier, which was responsible for a high incidence of rejection in extensively T cell-depleted transplants, has successfully been overcome. There is no doubt that the turning point in the history of the T cell-depleted mismatched transplant was the infusion of a megadose of stem cells, a principle which had been amply demonstrated in animal models.
To date, the results obtained show that remarkable progress has been made in several areas. Full donor-type engraftment is successful and sustained in over 90% of recipients, when megadoses of highly purified CD34
+ cells are given after highly immuno-and myelo-ablative conditioning regimens containing total body irradiation plus thiotepa, fludarabine and anti-thymocyte globulin (ATG) or based on chemotherapy alone (mainly in children). Graft-versus-host disease is almost fully prevented when using CD34 + cell selection devices. Following such procedures, the graft is extensively depleted of T cells, so that the mean T cell content does not exceed 1-2 × 10 4 cells/kg body weight. It is worth noting that the inclusion of ATG or OKT3 in conditioning regimens also contributes in reducing the incidence of graft-versus-host disease, because it exerts an in vivo T cell depletion of the inoculum. Furthermore, efficient purification of the graft has the corollary of reducing B lymphocyte contamination, thus almost completely preventing B lymphoproliferative disorders.
Growing evidence suggests that cells within the CD34 + cell population are endowed with marked veto activity. The term 'veto' relates to the ability of cells to neutralize cytotoxic T lymphocyte precursors (CTLp) directed against their antigens. When purified CD34
+ cells are added to bulk mixed lymphocyte cultures, they suppress the development of CTLp into mature CTL against matched stimulators but not against stimulators from a third party. This effect can be exhibited only if the cells are added within the first 48 h of mixed leukocyte reaction (MLR). Therefore, the veto effect of these cells seems to be directed against CTLp, but does not affect differentiated anti-donor CTL. Preliminary data suggest that the veto activity of human CD34
+ cells, similarly to other veto cells described in the literature, is mediated by apoptosis (Gur et al, unpublished). However it seems that both CD8 and Fas ligand (FasL), shown to be crucial for the veto activity of CD8 CTL, are not likely mediators of this activity.
One remarkable phenomenon is that in many cases the HLA disparity triggers donor-versus-recipient natural killer (NK) cell alloreactivity. These transplants offer major advantages in terms of controlling AML relapse and better engraftment rates and the benefits can be predicted pretransplant by using HLA typing to select the NK alloreactive donor.
The haploidentical stem cell transplant has been associated with high infection-related mortality rates, which were due to its being used as 'last chance treatment' for very high risk patients. Most recipients had been heavily pre-treated, had a long history of disease and were in relapse at transplant, all of which factors led to bacterial and fungal colonization at transplant. The slow immunological reconstitution, due to the extensive T cell depletion of the inoculum, also made a contribution to the mortality rate. However, suspending post-transplant G-CSF treatment, which exerted immunosuppressive effects, greatly improved the number and functions of posttransplant CD4 + cells. The benefits could only be assessed in patients who were transplanted in the early stages of the disease. Indeed, the probability of transplant-related mortality in patients in high risk first or second complete remission (CRI or CRII) closely approaches reports from T cell-replete transplants from HLA-identical siblings. Furthermore, in a transplant setting without the risk of graft-versus-host disease and without any post-transplant immunosuppressive therapy, the immunological reconstitution may be improved even more, by exploiting biological mechanisms such as infusion of donor lymphocytes after in vitro depletion of the alloreactive cells and activation against specific sources of infection.
The combination of all these achievements -lower regimen-related toxicity, better engraftment rates, no graft-versushost disease, the benefits of NK cell alloreactivity and reduced transplant-related mortality -led to a probability of event-free survival in patients who are transplanted in remission, which compares favorably with outcome in matched transplants carried out in patients at the same stage of disease. The time seems to be ripe for a multicenter, intention-to-treat clinical study comparing haploidentical transplant with matched unrelated and cord blood transplants. A major achievement of the Perugia and the Chicago meetings, was the establishment of consensus regarding recommendations for a prospective multicenter study. These recommendations, which are described in detail in this issue, address the conditioning regimen, the technology for graft processing and the supportive care for a haploidentical transplant. It is hoped that the results to date will be confirmed on a large scale and that the outcome can be analyzed statistically. If results overlap or are even better than alternative forms of transplant, one might wonder whether it is still necessary to search for a donor outside the family circle.
Leukemia
